Metabolic medicines
Tirzepatide
An incretin medicine used for selected diabetes, obesity and obesity-associated sleep-apnea indications.
Medical uses / indication-specific evidence
Also known as: Mounjaro · Zepbound
Practical use
Applying the explained evidence
- Where it fits
- An incretin medicine used for selected diabetes, obesity and obesity-associated sleep-apnea indications.
- Put the information into practice
- The goal is an appropriate medical outcome, not the fastest possible loss of scale weight. Drug comparisons require comparable trial populations and methods.
- The outcome being treated
- Identify whether the evidence concerns a diagnosed condition, body weight, appetite or a laboratory marker. Check which outcomes were measured and over what follow-up before transferring a finding to another goal.
- Keep this limit in view
- These are separate research arms, not a menu for choosing a personal dose. Comparing their means with a semaglutide result from another trial does not establish head-to-head superiority: populations, follow-up and trial methods differ.
Overview
Tirzepatide affects incretin signaling, glucose-dependent insulin release, stomach emptying and appetite. Its approved uses depend on the specific product and patient criteria.
Risks and limitations
Nausea, vomiting, diarrhea and constipation are common. Persistent severe abdominal pain and allergic symptoms require prompt evaluation. Rodent thyroid-tumor findings led to a warning; human relevance is uncertain. Other medicines, digestive disorders, kidney disease and pregnancy need clinical review.
How to read this
The goal is an appropriate medical outcome, not the fastest possible loss of scale weight. Drug comparisons require comparable trial populations and methods.
Research explained
SURMOUNT-1: weight change at 72 weeks
Who was studied
2,539 adults with obesity, or overweight with a weight-related complication, excluding diabetes; randomized to three tirzepatide groups or placebo.
- Tirzepatide: lowest-exposure arm
- -15 %
- Tirzepatide: middle arm
- -19.5 %
- Tirzepatide: highest-exposure arm
- -20.9 %
- Placebo
- -3.1 %
What was found
Across the three active groups, mean weight change was −15.0%, −19.5% and −20.9%, versus −3.1% with placebo. The study included a 20-week escalation period.
What it cannot establish
These are separate research arms, not a menu for choosing a personal dose. Comparing their means with a semaglutide result from another trial does not establish head-to-head superiority: populations, follow-up and trial methods differ.
Read the original studySources
SURMOUNT-1: weight change at 72 weeks
Sources checked 2026-09-28.
General education; not a personal treatment plan.